Akathisia: Medication-Related Restlessness and Treatment Review

Akathisia is a distressing pattern of inner restlessness, often accompanied by an urge to move. It can occur with antipsychotics and some other medicines, particularly around treatment changes. It may be mistaken for anxiety or worsening psychiatric symptoms, so a prompt, specific medication review is important.

What akathisia can feel and look like

A person may feel unable to sit still, pace repeatedly, shift weight, move their legs, or describe an unbearable internal agitation. The subjective distress can be severe even when visible movement is limited. Asking directly about the urge to move helps avoid overlooking the experience.

Akathisia is different from simply choosing to be active. It can interfere with sleep, concentration, appointments, and the ability to continue treatment. A respectful assessment should take the person's description seriously rather than treating restlessness as noncooperation.

Timing and medication history are important

Symptoms may begin after starting or increasing an antipsychotic, switching treatment, or changing other medicines. They can also occur in more complex time patterns. The clinician needs the exact products, doses, recent changes, and other substances to assess the likely relationship.

Some antidepressants and other drugs can also be involved. Do not assume that a medicine is excluded because it is not an antipsychotic. A full list and a simple timeline are more useful than identifying only the most recently prescribed product.

Assessment distinguishes several causes of restlessness

Anxiety, mania, psychotic agitation, restless legs syndrome, withdrawal, pain, and other medical problems can resemble aspects of akathisia. Clinicians may use observation and a structured assessment scale alongside the person's account. The distinction matters because treatments are not interchangeable.

Increasing an antipsychotic for presumed worsening illness can aggravate medication-related akathisia in some situations. Conversely, abruptly stopping treatment can create other problems. The goal is an accurate assessment before changing the regimen.

Useful information to report

• Whether there is an inner urge to move and whether movement provides temporary relief.
• When symptoms began relative to starting, increasing, reducing or switching medication.
• Whether restlessness affects sleep, concentration or ability to remain seated.
• All prescribed and nonprescription medicines, supplements and substances.
• Any associated mood change, distress or thoughts of self-harm.
• Previous similar reactions and what was done at the time.

Treatment should address the prescribing plan first

Depending on the circumstances, the clinician may consider reducing an implicated medicine, simplifying antipsychotic combinations, or switching to another option. This requires balancing symptom control and the burden of akathisia. The evidence and individual response should guide the decision.

Selected add-on treatments, including propranolol or other medicines, may be considered when suitable. These are not universal remedies and have their own contraindications, interactions, and adverse effects. Some drugs used for other movement symptoms are not the best approach for akathisia.

Severe distress warrants timely help

Akathisia can be intensely uncomfortable and should not be left until a distant routine appointment if severe. New self-harm thoughts, inability to stay safe, or extreme deterioration requires urgent mental-health support. The association between akathisia and safety concerns should be assessed without assuming a single cause.

Do not self-treat with alcohol, unprescribed sedatives, or repeated dose changes. Contact the prescribing team and describe the symptoms clearly. After an adjustment, follow-up should assess restlessness, psychiatric symptoms, sleep, and any new adverse effects.

Internal restlessness can matter even when movement is subtle

Akathisia can involve an intense internal urge to move, with pacing, shifting position or difficulty sitting still. Some people mainly describe discomfort rather than obvious movement during an appointment. The person's account therefore matters and should not be dismissed because the clinician sees them sitting briefly. Explain how the sensation affects sleep, meals, conversation or the ability to remain in one place.

The antipsychotic overview provides context for medicines that may be involved. Tell the team when the experience began and whether it followed initiation, a dose change or another treatment. The timeline supports assessment without establishing the cause alone. A short description of what makes it worse or temporarily relieves it may be useful. Do not assume that the symptom reflects poor cooperation or a need for more psychiatric medication. It should be assessed as a possible adverse effect alongside other explanations.

Akathisia, anxiety, restless legs and agitation need distinction

Several conditions can cause a person to feel restless or move repeatedly. Anxiety, agitation, restless-legs symptoms, withdrawal and other movement problems may overlap with akathisia. Their patterns and management differ. A clinical assessment may include the subjective experience, observation, timing and a structured scale. An internet checklist cannot reliably determine the diagnosis.

The risperidone profile and olanzapine guide offer medicine context, but the full regimen needs review. Tell the clinician about antidepressants, anti-nausea medicines and other exposures as well as antipsychotics. Do not use somebody else's treatment for a similar-looking symptom. A review should examine whether the original condition has changed, whether a medicine effect is likely and which other causes need consideration. Clear distinction matters because treating restlessness only as worsening illness can lead to a medication change that does not address the problem and may add to the burden.

Reviewing the responsible regimen before adding treatment

Management should consider the original prescription and its benefit-risk balance. The clinician may review dose, combinations or a switch where appropriate before deciding on an additional medicine. Any add-on has its own contraindications and adverse effects. A remedy discussed in research is not a personal instruction to take it, and high-dose supplements are not automatically safe.

Ask what the team believes is causing the symptom, what options are feasible and how psychiatric stability will be protected. Do not abruptly stop an antipsychotic or change a dose independently. If more than one medicine has similar effects, a coordinated review can clarify which contributions matter. The plan should identify the intended outcome and follow-up, not merely suppress visible movement while inner distress remains. A medication that helps the original illness can still need adjustment when akathisia becomes unacceptable. The person's comfort and ability to function belong in the decision.

Severe distress requires timely support

Akathisia can be profoundly distressing. Tell the clinician if you feel unable to cope, cannot sleep or have thoughts of self-harm. These concerns require prompt attention rather than being postponed to a routine appointment. Immediate danger or inability to stay safe warrants urgent help. The team should assess safety and the likely cause together.

A trusted person may help communicate the change with your consent, but support should not substitute for clinical assessment. Keep the medication list and timeline available so urgent clinicians can understand recent changes. Do not attempt to relieve the distress with illicit substances, extra sedatives or an improvised combination. After initial management, ask for follow-up to confirm whether the symptoms and daily impact improved. A difficult reaction should lead to a clearer, more acceptable treatment plan, with the experience recorded for future prescribing rather than dismissed once the most visible restlessness settles.

Making the next medication discussion useful

Bring one current list of medicines to the appointment, including the exact product, prescribed instructions, over-the-counter remedies, supplements and any medicines you take only occasionally. If the list in a clinic record is different from what you actually use, say so. Understanding the difference is more useful than trying to give an answer that sounds correct. A photograph of packaging can help clarify an unfamiliar brand or formulation.

Choose two or three priorities before the visit. These might be a persistent symptom, a side effect affecting daily life, a monitoring result or concern about continuing treatment. Describe when the problem began and whether it followed a change in medicine, illness, sleep or substance use. You do not have to diagnose the cause yourself. A clear timeline helps the clinician consider several explanations without automatically attributing everything to the psychiatric condition.

Leave with an agreed next step and a review date. If the plan changes, ask for written instructions that explain what each medicine is intended to do and whom to contact if a problem occurs. Check that the pharmacy and other prescribers have the updated plan. A useful review ends with responsibilities assigned, not simply with a recommendation to monitor the situation. Shared decisions should include your preferences, the available evidence and the practical ability to carry out the plan.

Related Medication and Treatment Guides

• Risperdal
• What are Antipsychotics
• Olanzapine: effects, side effects, monitoring and safe use
• Explore the Medication Guide